Astrana Health 2025 revenue up 56% to $3.18 billion; flags internal control weakness
Astrana Health reported full-year 2025 revenue of $3.18 billion, up 56%, and fourth-quarter revenue of $950.5 million, up 43%. Full-year GAAP net income attributable to the company fell to $22.5 million from $43.1 million, and the company said it expects to report a material weakness in internal control over financial reporting, which will delay its annual report on Form 10-K.
Key points
- Full-year 2025 revenue of $3,181.8 million, up 56%; adjusted EBITDA of $205.4 million, up 21%
- Full-year 2025 diluted EPS of $0.46 versus $0.90 in 2024; adjusted diluted EPS of $2.20 versus $1.94
- Company will file Form 12b-25 to extend the 10-K deadline, expects a material weakness tied to acquisition and purchase accounting, and expects to file within the 15-day extension period
- Board raised the share repurchase authorization from $50 million to $100 million; $35.9 million remained available as of December 31, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 02, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.